Immunoglobulin single variable domain antibody against RSV prefusion F protein

US11248039B2 · kind B2 · utility

Assignees

• VIB VZW · BE
• UNNVERSITEIT GENT
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• TRUSTEES OF DARTMOUTH COLLEGE · US

Inventors

• Xavier Saelens · Ieper, BE
• Bert Schepens · Evergem, BE
• Iebe Rossey · Gentbrugge, BE
• Barney Graham · Rockville, US
• Jason McLellan · Austin, US
• Morgan Gilman · White River Junction, US

Key dates

• Filing date: Sep 10, 2019
• Grant date: Feb 15, 2022
• Expiry date: Sep 10, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.